2023-02-282024-02-292024-02-29false14693790DR SALIE CLINICS LTD2024-11-2986230iso4217:GBPxbrli:pure146937902023-02-28146937902024-02-29146937902023-02-282024-02-29146937902023-02-27146937902023-02-27146937902023-02-272023-02-2714693790bus:SmallEntities2023-02-282024-02-2914693790bus:AuditExempt-NoAccountantsReport2023-02-282024-02-2914693790bus:FullAccounts2023-02-282024-02-2914693790bus:PrivateLimitedCompanyLtd2023-02-282024-02-2914693790core:WithinOneYear2024-02-2914693790core:AfterOneYear2024-02-2914693790core:WithinOneYear2023-02-2714693790core:AfterOneYear2023-02-2714693790core:ShareCapital2024-02-2914693790core:SharePremium2024-02-2914693790core:RevaluationReserve2024-02-2914693790core:OtherReservesSubtotal2024-02-2914693790core:RetainedEarningsAccumulatedLosses2024-02-2914693790core:ShareCapital2023-02-2714693790core:SharePremium2023-02-2714693790core:RevaluationReserve2023-02-2714693790core:OtherReservesSubtotal2023-02-2714693790core:RetainedEarningsAccumulatedLosses2023-02-2714693790core:LandBuildings2024-02-2914693790core:PlantMachinery2024-02-2914693790core:Vehicles2024-02-2914693790core:FurnitureFittings2024-02-2914693790core:OfficeEquipment2024-02-2914693790core:NetGoodwill2024-02-2914693790core:IntangibleAssetsOtherThanGoodwill2024-02-2914693790core:ListedExchangeTraded2024-02-2914693790core:UnlistedNon-exchangeTraded2024-02-2914693790core:LandBuildings2023-02-2714693790core:PlantMachinery2023-02-2714693790core:Vehicles2023-02-2714693790core:FurnitureFittings2023-02-2714693790core:OfficeEquipment2023-02-2714693790core:NetGoodwill2023-02-2714693790core:IntangibleAssetsOtherThanGoodwill2023-02-2714693790core:ListedExchangeTraded2023-02-2714693790core:UnlistedNon-exchangeTraded2023-02-2714693790core:LandBuildings2023-02-282024-02-2914693790core:PlantMachinery2023-02-282024-02-2914693790core:Vehicles2023-02-282024-02-2914693790core:FurnitureFittings2023-02-282024-02-2914693790core:OfficeEquipment2023-02-282024-02-2914693790core:NetGoodwill2023-02-282024-02-2914693790core:IntangibleAssetsOtherThanGoodwill2023-02-282024-02-2914693790core:ListedExchangeTraded2023-02-282024-02-2914693790core:UnlistedNon-exchangeTraded2023-02-282024-02-2914693790core:MoreThanFiveYears2023-02-282024-02-2914693790core:Non-currentFinancialInstruments2024-02-2914693790core:Non-currentFinancialInstruments2023-02-2714693790dpl:CostSales2023-02-282024-02-2914693790dpl:DistributionCosts2023-02-282024-02-2914693790core:LandBuildings2023-02-282024-02-2914693790core:PlantMachinery2023-02-282024-02-2914693790core:Vehicles2023-02-282024-02-2914693790core:FurnitureFittings2023-02-282024-02-2914693790core:OfficeEquipment2023-02-282024-02-2914693790dpl:AdministrativeExpenses2023-02-282024-02-2914693790core:NetGoodwill2023-02-282024-02-2914693790core:IntangibleAssetsOtherThanGoodwill2023-02-282024-02-2914693790dpl:GroupUndertakings2023-02-282024-02-2914693790dpl:ParticipatingInterests2023-02-282024-02-2914693790dpl:GroupUndertakingscore:ListedExchangeTraded2023-02-282024-02-2914693790core:ListedExchangeTraded2023-02-282024-02-2914693790dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-02-282024-02-2914693790core:UnlistedNon-exchangeTraded2023-02-282024-02-2914693790dpl:CostSales2023-02-272023-02-2714693790dpl:DistributionCosts2023-02-272023-02-2714693790core:LandBuildings2023-02-272023-02-2714693790core:PlantMachinery2023-02-272023-02-2714693790core:Vehicles2023-02-272023-02-2714693790core:FurnitureFittings2023-02-272023-02-2714693790core:OfficeEquipment2023-02-272023-02-2714693790dpl:AdministrativeExpenses2023-02-272023-02-2714693790core:NetGoodwill2023-02-272023-02-2714693790core:IntangibleAssetsOtherThanGoodwill2023-02-272023-02-2714693790dpl:GroupUndertakings2023-02-272023-02-2714693790dpl:ParticipatingInterests2023-02-272023-02-2714693790dpl:GroupUndertakingscore:ListedExchangeTraded2023-02-272023-02-2714693790core:ListedExchangeTraded2023-02-272023-02-2714693790dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-02-272023-02-2714693790core:UnlistedNon-exchangeTraded2023-02-272023-02-2714693790core:NetGoodwill2024-02-2914693790core:IntangibleAssetsOtherThanGoodwill2024-02-2914693790core:LandBuildings2024-02-2914693790core:PlantMachinery2024-02-2914693790core:Vehicles2024-02-2914693790core:FurnitureFittings2024-02-2914693790core:OfficeEquipment2024-02-2914693790core:AfterOneYear2024-02-2914693790core:WithinOneYear2024-02-2914693790core:ListedExchangeTraded2024-02-2914693790core:UnlistedNon-exchangeTraded2024-02-2914693790core:ShareCapital2024-02-2914693790core:SharePremium2024-02-2914693790core:RevaluationReserve2024-02-2914693790core:OtherReservesSubtotal2024-02-2914693790core:RetainedEarningsAccumulatedLosses2024-02-2914693790core:NetGoodwill2023-02-2714693790core:IntangibleAssetsOtherThanGoodwill2023-02-2714693790core:LandBuildings2023-02-2714693790core:PlantMachinery2023-02-2714693790core:Vehicles2023-02-2714693790core:FurnitureFittings2023-02-2714693790core:OfficeEquipment2023-02-2714693790core:AfterOneYear2023-02-2714693790core:WithinOneYear2023-02-2714693790core:ListedExchangeTraded2023-02-2714693790core:UnlistedNon-exchangeTraded2023-02-2714693790core:ShareCapital2023-02-2714693790core:SharePremium2023-02-2714693790core:RevaluationReserve2023-02-2714693790core:OtherReservesSubtotal2023-02-2714693790core:RetainedEarningsAccumulatedLosses2023-02-2714693790core:NetGoodwill2023-02-2714693790core:IntangibleAssetsOtherThanGoodwill2023-02-2714693790core:LandBuildings2023-02-2714693790core:PlantMachinery2023-02-2714693790core:Vehicles2023-02-2714693790core:FurnitureFittings2023-02-2714693790core:OfficeEquipment2023-02-2714693790core:AfterOneYear2023-02-2714693790core:WithinOneYear2023-02-2714693790core:ListedExchangeTraded2023-02-2714693790core:UnlistedNon-exchangeTraded2023-02-2714693790core:ShareCapital2023-02-2714693790core:SharePremium2023-02-2714693790core:RevaluationReserve2023-02-2714693790core:OtherReservesSubtotal2023-02-2714693790core:RetainedEarningsAccumulatedLosses2023-02-2714693790core:AfterOneYear2023-02-282024-02-2914693790core:WithinOneYear2023-02-282024-02-2914693790core:Non-currentFinancialInstrumentscore:CostValuation2023-02-282024-02-2914693790core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-02-282024-02-2914693790core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-02-282024-02-2914693790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-02-282024-02-2914693790core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-02-282024-02-2914693790core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-02-282024-02-2914693790core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-02-282024-02-2914693790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-02-282024-02-2914693790core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-02-282024-02-2914693790core:Non-currentFinancialInstrumentscore:CostValuation2024-02-2914693790core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-02-2914693790core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-02-2914693790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-02-2914693790core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-02-2914693790core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-02-2914693790core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-02-2914693790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-02-2914693790core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-02-2914693790core:Non-currentFinancialInstrumentscore:CostValuation2023-02-2714693790core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-02-2714693790core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-02-2714693790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-02-2714693790core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-02-2714693790core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-02-2714693790core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-02-2714693790core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-02-2714693790core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-02-2714693790bus:Director12023-02-282024-02-29

DR SALIE CLINICS LTD

Registered Number
14693790
(England and Wales)

Unaudited Financial Statements for the Period ended
29 February 2024

DR SALIE CLINICS LTD
Company Information
for the period from 28 February 2023 to 29 February 2024

Director

SALIE-PARKER, Rushdiyah, Dr

Registered Address

Havenbrook
Clacton Road
Colchester
CO7 7DB

Registered Number

14693790 (England and Wales)
DR SALIE CLINICS LTD
Balance Sheet as at
29 February 2024

Notes

2024

£

£

Fixed assets
Tangible assets3643
643
Current assets
Stocks42,000
Debtors51
Cash at bank and on hand11,080
13,081
Creditors amounts falling due within one year6(11,875)
Net current assets (liabilities)1,206
Total assets less current liabilities1,849
Net assets1,849
Capital and reserves
Called up share capital1
Profit and loss account1,848
Shareholders' funds1,849
The financial statements were approved and authorised for issue by the Director on 29 November 2024, and are signed on its behalf by:
SALIE-PARKER, Rushdiyah, Dr
Director
Registered Company No. 14693790
DR SALIE CLINICS LTD
Notes to the Financial Statements
for the period ended 29 February 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Reducing balance (%)
Office Equipment25
Stocks and work in progress
Stocks are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basic financial assets Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised. Classification of financial liabilities Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Basic financial liabilities Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
2.Average number of employees

2024
Average number of employees during the year1
3.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
Additions683683
At 29 February 24683683
Depreciation and impairment
Charge for year4040
At 29 February 244040
Net book value
At 29 February 24643643
At 27 February 23--
4.Stocks

2024

£
Finished goods2,000
Total2,000
5.Debtors: amounts due within one year

2024

£
Other debtors1
Total1
6.Creditors: amounts due within one year

2024

£
Taxation and social security10,854
Other creditors301
Accrued liabilities and deferred income720
Total11,875
7.Related party transactions
Included in other creditors falling due within one year are amount due to the director £300.
8.Change in reporting period and impact on comparability
Reporting period This is the first time the company has presented its financial statements since its incorporation. Hence, the financial statements presented are for the period of more than twelve months with no comparatives.